Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 12, 2015, Pages 2088-2108

  Vierling, John M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acute Liver Failure; Autoimmune Hepatitis; Hepatocellular Carcinoma

Indexed keywords

AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DRUG METABOLITE; EVEROLIMUS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; INFLIXIMAB; LIVER KIDNEY MICROSOME ANTIBODY 1; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ACUTE HEPATITIS; ACUTE LIVER FAILURE; ADAPTIVE IMMUNITY; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; HEMOLYTIC UREMIC SYNDROME; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTRAHEPATIC CHOLESTASIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MATERNAL CARE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; OVERLAP SYNDROME; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); TOXIC HEPATITIS; UNITED STATES; UNSPECIFIED SIDE EFFECT; AGE; BLOOD; CHOLANGITIS, SCLEROSING; CYTOCHEMISTRY; GEOGRAPHY; HEPATITIS, AUTOIMMUNE; INCIDENCE; LIVER CIRRHOSIS, BILIARY; PATHOLOGY;

AGE FACTORS; AUTOANTIBODIES; CHOLANGITIS, SCLEROSING; GEOGRAPHY; HEPATITIS, AUTOIMMUNE; HISTOCYTOCHEMISTRY; HUMANS; INCIDENCE; LIVER CIRRHOSIS, BILIARY; SEX FACTORS; TRANSAMINASES;

EID: 84944387196     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.08.012     Document Type: Review

References (223)

1. Manns M.P., Czaja A.J., Gorham J.D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
2. Heneghan M.A., Yeoman A.D., Verma S., et al. Autoimmune hepatitis. Lancet 2013, 382:1433-1444.
3. Sahebjam F., Vierling J.M. Autoimmune hepatitis. Front Med 2015, 9:187-219.
4. Liberal R., Longhi M.S., Mieli-Vergani G., et al. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011, 25:653-664.
5. Vierling J.M. The pathogenesis of autoimmune hepatitis. Autoimmune hepatitis: a guide for practicing clinicians 2012, 3-49. Humana Press, New York. G.M. Hirschfield, E.J. Heathcote (Eds.).
6. Manns M.P., Lohse A.W., Vergani D. Autoimmune hepatitis: update 2015. J Hepatol 2015, 62:S100-S111.
7. Czaja A.J., Freese D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002, 36:479-497.
8. Ngu J.H., Bechly K., Chapman B.A., et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women?. J Gastroenterol Hepatol 2010, 25:1681-1686.
9. Gregorio G.V., Portmann B., Reid F., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997, 25:541-547.
10. Boberg K.M. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002, 6:635-647.
11. Czaja A.J. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol 2013, 27:417-423.
12. Boberg K.M., Chapman R.W., Hirschfield G.M., et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011, 54:374-385.
13. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
14. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
15. Manns M.P., Woynarowski M., Kreisel W., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010, 139:1198-1206.
16. Ilyas J.A., O'Mahony C.A., Vierling J.M. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol 2011, 25:765-782.
17. Liberal R., Grant C.R., Longhi M.S., et al. Diagnostic criteria of autoimmune hepatitis. Autoimmun Rev 2014, 13:435-440.
18. Stravitz R.T., Lefkowitch J.H., Fontana R.J., et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011, 53:517-526.
19. Tanaka A. Acute presentation of autoimmune hepatitis: how to find and manage still remains unsolved. Hepatol Res 2013, 43:577-579.
20. Czaja A.J. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci 2013, 58:897-914.
21. Vierling J.M. Diagnosis and treatment of autoimmune hepatitis. Curr Gastroenterol Rep 2012, 14:25-36.
22. Scott J., Gollan J.L., Samourian S., et al. Wilson's disease, presenting as chronic active hepatitis. Gastroenterology 1978, 74:645-651.
23. Milkiewicz P., Saksena S., Hubscher S.G., et al. Wilson's disease with superimposed autoimmune features: report of two cases and review. J Gastroenterol Hepatol 2000, 15:570-574.
24. Deutsch M., Emmanuel T., Koskinas J. Autoimmune hepatitis or Wilson's disease, a clinical dilemma. Hepat Mon 2013, 13:e7872.
25. Santos R.G., Alissa F., Reyes J., et al. Fulminant hepatic failure: Wilson's disease or autoimmune hepatitis? implications for transplantation. Pediatr Transplant 2005, 9:112-116.
26. Czaja A.J. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology 2011, 140:1472-1480.
27. Gatselis N.K., Zachou K., Papamichalis P., et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?. Dig Liver Dis 2010, 42:807-812.
28. Abdollahi M.R., Somi M.H., Faraji E. Role of international criteria in the diagnosis of autoimmune hepatitis. World J Gastroenterol 2013, 19:3629-3633.
29. Li Y., Peng M., Gong G. Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis. Exp Ther Med 2014, 7:131-136.
30. Qiu D., Wang Q., Wang H., et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol 2011, 54:340-347.
31. Czaja A.J. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013, 58:326-343.
32. Strassburg C.P. Autoimmune hepatitis. Dig Dis 2013, 31:155-163.
33. Krawitt E.L. Discrimination of autoimmune hepatitis: autoantibody typing and beyond. J Gastroenterol 2011, 46(Suppl 1):39-41.
34. Couto C.A., Bittencourt P.L., Porta G., et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology 2014, 59:592-600.
35. Czaja A.J. Autoantibody-negative autoimmune hepatitis. Dig Dis Sci 2012, 57:610-624.
36. Czaja A.J. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci 2011, 56:545-554.
37. Vergani D., Alvarez F., Bianchi F.B., et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004, 41:677-683.
38. Liu H., Norman G.L., Shums Z., et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 2010, 35:436-442.
39. Longhi M.S., Ma Y., Mieli-Vergani G., et al. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010, 34:7-14.
40. Czaja A.J. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010, 55:2144-2161.
41. Montano-Loza A.J., Shums Z., Norman G.L., et al. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012, 32:85-92.
42. Schramm C., Herkel J., Beuers U., et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006, 101:556-560.
43. Guindi M. Histology of autoimmune hepatitis and its variants. Clin Liver Dis 2010, 14:577-590.
44. Efe C., Wahlin S., Ozaslan E., et al. Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. Scand J Gastroenterol 2013, 48:504-508.
45. Pischke S., Gisa A., Suneetha P.V., et al. Increased HEV seroprevalence in patients with autoimmune hepatitis. PLoS One 2014, 9:e85330.
46. Ju H.Y., Jang J.Y., Jeong S.W., et al. The clinical features of drug-induced liver injury observed through liver biopsy: focus on relevancy to autoimmune hepatitis. Clin Mol Hepatol 2012, 18:213-218.
47. Kobayashi M., Kakuda Y., Harada K., et al. Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis. World J Gastroenterol 2014, 20:3597-3608.
48. Te H.S., Koukoulis G., Ganger D.R. Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut 1997, 41:269-271.
49. Hofer H., Oesterreicher C., Wrba F., et al. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006, 59:246-249.
50. Bjornsson E., Talwalkar J., Treeprasertsuk S., et al. Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol 2011, 9:57-63.
51. Czaja A.J. Cholestatic phenotypes of autoimmune hepatitis. Clin Gastroenterol Hepatol 2014, 12:1430-1438.
52. Czaja A.J. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. J Hepatol 2006, 44:251-252.
53. Roll J., Boyer J.L., Barry D., et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983, 308:1-7.
54. Christensen E., Neuberger J., Crowe J., et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985, 89:1084-1091.
55. Mitchison H.C., Palmer J.M., Bassendine M.F., et al. A controlled trial of prednisolone treatment in primary biliary cirrhosis: three-year results. J Hepatol 1992, 15:336-344.
56. Wiesner R.H., Ludwig J., Lindor K.D., et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990, 322:1419-1424.
57. Heathcote J., Ross A., Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 1976, 70:656-660.
58. Chazouilleres O., Wendum D., Serfaty L., et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
59. Kuiper E.M., Zondervan P.E., van Buuren H.R. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010, 8:530-534.
60. Gossard A.A., Lindor K.D. Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int 2007, 27:1086-1090.
61. Yokokawa J., Saito H., Kanno Y., et al. Overlap of primary biliary cirrhosis and autoimmune hepatitis: characteristics, therapy, and long term outcomes. J Gastroenterol Hepatol 2010, 25:376-382.
62. Heurgue A., Vitry F., Diebold M.D., et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol 2007, 31:17-25.
63. Silveira M.G., Talwalkar J.A., Angulo P., et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007, 102:1244-1250.
64. Efe C., Wahlin S., Ozaslan E., et al. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol 2012, 24:531-534.
65. Coss A.E., Granados J., Uribe M., et al. Does HLA-DR7 differentiate the overlap syndrome of auto-immune hepatitis-primary biliary cirrhosis (AIH-PBC) from those with auto-immune hepatitis type 1?. Ann Hepatol 2011, 10:28-32.
66. Levy C., Naik J., Giordano C., et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol 2013.
67. Lee H., Stapp R.T., Ormsby A.H., et al. The usefulness of IgG and IgM immunostaining of periportal inflammatory cells (plasma cells and lymphocytes) for the distinction of autoimmune hepatitis and primary biliary cirrhosis and their staining pattern in autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Am J Clin Pathol 2010, 133:430-437.
68. Cabibi D., Tarantino G., Barbaria F., et al. Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. Dig Liver Dis 2010, 42:585-592.
69. Kaya M., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000, 33:537-542.
70. Hunter M., Loughrey M.B., Gray M., et al. Evaluating distinctive features for early diagnosis of primary sclerosing cholangitis overlap syndrome in adults with autoimmune hepatitis. Ulster Med J 2011, 80:15-18.
71. Floreani A., Rizzotto E.R., Ferrara F., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005, 100:1516-1522.
72. Ozaslan E., Efe C., Akbulut S., et al. Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis. Hepatogastroenterology 2010, 57:441-446.
73. Czaja A.J. Variant forms of autoimmune hepatitis. Curr Gastroenterol Rep 1999, 1:63-70.
74. Czaja A.J. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013, 38:343-364.
75. Culver E.L., Chapman R.W. Systematic review: management options for primary sclerosing cholangitis and its variant forms-IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther 2011, 33:1273-1291.
76. Umemura T., Zen Y., Hamano H., et al. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. J Gastroenterol 2011, 46(Suppl 1):48-55.
77. Suzuki A., Brunt E.M., Kleiner D.E., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011, 54:931-939.
78. Lucena M.I., Kaplowitz N., Hallal H., et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011, 55:820-827.
79. Kaymakoglu S. Drug-induced hepatitis, drug-induced autoimmunity or classical autoimmune hepatitis: how can we differentiate?. Turk J Gastroenterol 2004, 15:123-125.
80. Fujiwara K., Yokosuka O. Histological discrimination between autoimmune hepatitis and drug-induced liver injury. Hepatology 2012, 55:657.
81. Czaja A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56:958-976.
82. Bjornsson E., Talwalkar J., Treeprasertsuk S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040-2048.
83. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011, 89:806-815.
84. Loria P., Lonardo A., Leonardi F., et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003, 48:2173-2181.
85. Cotler S.J., Kanji K., Keshavarzian A., et al. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 2004, 38:801-804.
86. Badiani R.G., Becker V., Perez R.M., et al. Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis?. World J Gastroenterol 2010, 16:3704-3708.
87. Rezaee Zavareh M.S., Alavian S.M., Karimisari H., et al. Occult hepatitis C virus infection in patients with autoimmune hepatitis. Hepat Mon 2014, 14:e16089.
88. Unzueta A., Rakela J. Hepatitis E infection in liver transplant recipients. Liver Transpl 2014, 20:15-24.
89. Moal V., Legris T., Burtey S., et al. Infection with hepatitis E virus in kidney transplant recipients in southeastern France. J Med Virol 2013, 85:462-471.
90. Yasui S., Fujiwara K., Yonemitsu Y., et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol 2011, 46:378-390.
91. Czaja A.J. Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis 1997, 15:125-144.
92. Efe C., Ozaslan E., Nasiroglu N., et al. The development of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome during the course of connective tissue diseases: report of three cases and review of the literature. Dig Dis Sci 2010, 55:2417-2421.
93. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
94. Sherman M., Bruix J., Porayko M., et al. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012, 56:793-796.
95. Czaja A.J. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci 2013, 58:1459-1476.
96. Danielsson B.A., Almer S., Prytz H., et al. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis: a long-term follow-up study in 634 Swedish patients. Scand J Gastroenterol 2015, 50:217-223.
97. Ohira H., Abe K., Takahashi A., et al. Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan. J Gastroenterol 2013, 48:109-114.
98. Yeoman A.D., Al-Chalabi T., Karani J.B., et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008, 48:863-870.
99. Shah A.M., Malhotra A., Kothari S., et al. Reversal of liver cirrhosis in autoimmune hepatitis. Hepatogastroenterology 2011, 58:2115-2117.
100. Czaja A.J. Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther 2014, 39:385-406.
101. Yeoman A.D., Westbrook R.H., Zen Y., et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011, 53:926-934.
102. Muratori L., Muratori P., Lanzoni G., et al. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology 2010, 52:1857-1858.
103. Efe C., Kav T., Aydin C., et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. Dig Dis Sci 2014, 59:3035-3042.
104. Czaja A.J. Drug choices in autoimmune hepatitis: part A-steroids. Expert Rev Gastroenterol Hepatol 2012, 6:603-615.
105. Strassburg C.P. Therapeutic options to treat autoimmune hepatitis in 2009. Dig Dis 2010, 28:93-98.
106. Geier A., Gartung C., Dietrich C.G., et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003, 9:2681-2685.
107. Lohse A.W., Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol 2011, 54:837-839.
108. Lamers M.M., van Oijen M.G., Pronk M., et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010, 53:191-198.
109. Czaja A.J. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007, 13:953-955.
110. Ichai P., Duclos-Vallee J.C., Guettier C., et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007, 13:996-1003.
111. Kessler W.R., Cummings O.W., Eckert G., et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004, 2:625-631.
112. Villamil A.G., Casciato P., Eduardo M., et al. Fulminant autoimmune hepatitis type 1: clinical presentation, outcome and prognostic factors. Am J Transplant 2011, 5(suppl 11):278.
113. Verma S., Maheshwari A., Thuluvath P. Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes. Hepatology 2009, 49:1396-1397.
114. Nguyen T.M., Daubard M., Le G.C., et al. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis. Ther Drug Monit 2010, 32:433-437.
115. Ferucci E.D., Hurlburt K.J., Mayo M.J., et al. Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people. Can J Gastroenterol 2011, 25:21-27.
116. Czaja A.J., Carpenter H.A. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006, 51:968-975.
117. Gisbert J.P., Gomollon F., Cara C., et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 2007, 52:1262-1269.
118. Heneghan M.A., Allan M.L., Bornstein J.D., et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006, 45:584-591.
119. Hindorf U., Jahed K., Bergquist A., et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010, 52:106-111.
120. de Boer Y.S., van Gerven N.M., de Boer N.K., et al. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2013, 37:640-646.
121. Czaja A.J. Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. Aliment Pharmacol Ther 2014, 39:1043-1058.
122. van Gerven N.M., Verwer B.J., Witte B.I., et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013, 58:141-147.
123. Montano-Loza A.J., Carpenter H.A., Czaja A.J. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007, 27:507-515.
124. Werner M., Bjornsson E., Prytz H., et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding?. Scand J Gastroenterol 2007, 42:986-991.
125. Muratori P., Loffreda S., Muratori L., et al. Spontaneous remission of autoimmune hepatitis during pregnancy. Dig Liver Dis 2002, 34:608-609.
126. Westbrook R.H., Yeoman A.D., Kriese S., et al. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun 2012, 38:J239-J244.
127. Terrabuio D.R., Abrantes-Lemos C.P., Carrilho F.J., et al. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009, 43:350-356.
128. de Boer N.K., Jarbandhan S.V., de Graaf P., et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006, 101:1390-1392.
129. Samuel D., Riordan S., Strasser S., et al. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol 2004, 2:622-624.
130. Jothimani D., Cramp M.E., Mitchell J.D., et al. Treatment of autoimmune hepatitis: a review of current and evolving therapies. J Gastroenterol Hepatol 2011, 26:619-627.
131. Wang S.B., Wang J.H., Zheng R.H., et al. Deep cholestatic jaundice as the predominant manifestation in autoimmune hepatitis. Hepatogastroenterology 2010, 57:326-329.
132. Yoshioka Y., Taniai M., Hashimoto E., et al. Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: importance of corticosteroid therapy. Hepatol Res 2013.
133. Wolf D.C., Bojito L., Facciuto M., et al. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009, 54:2519-2522.
134. Baven-Pronk A.M., Coenraad M.J., van Buuren H.R., et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011, 34:335-343.
135. Umemura T., Zen Y., Hamano H., et al. IgG4 associated autoimmune hepatitis: a differential diagnosis for classical autoimmune hepatitis. Gut 2007, 56:1471-1472.
136. Chung H., Watanabe T., Kudo M., et al. Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int 2010, 30:222-231.
137. Frider B., Bruno A., Zylberman M., et al. Autoimmune cholangitis associated to IgG4 related sclerosing disease. Acta Gastroenterol Latinoam 2011, 41:55-59.
138. Strassburg C.P. Autoimmune hepatitis: new guidelines, new therapies. Dig Dis 2012, 30(Suppl 1):11-19.
139. Czaja A.J. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2009, 3:269-291.
140. Czaja A.J., Manns M.P. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010, 139:58-72.
141. Czaja A.J. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol 2010, 16:934-947.
142. Mayo M.J. Management of autoimmune hepatitis. Curr Opin Gastroenterol 2011, 27:224-230.
143. Yeoman A.D., Longhi M.S., Heneghan M.A. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther 2010, 31:771-787.
144. Vergani D., Mieli-Vergani G. Pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother 2011, 12:607-613.
145. Czaja A.J. Drug choices in autoimmune hepatitis: part B-nonsteroids. Expert Rev Gastroenterol Hepatol 2012, 6:617-635.
146. Selvarajah V., Montano-Loza A.J., Czaja A.J. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012, 36:691-707.
147. Czaja A.J. Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I. Inflamm Allergy Drug Targets 2012, 11:337-350.
148. D'Agostino D., Costaguta A., Alvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. Pediatrics 2013, 132:e526-e530.
149. Burak K.W., Swain M.G., Santodomingo-Garzon T., et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013, 27:273-280.
150. Grasland A., Sterpu R., Boussoukaya S., et al. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol 2012, 68:895-898.
151. Weiler-Normann C., Sebode M., Lohse A.W. Autoimmune hepatitis 2013 and beyond. Minerva Gastroenterol Dietol 2013, 59:133-141.
152. Kurowski J., Melin-Aldana H., Bass L., et al. Sirolimus as rescue therapy in pediatric autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2014, 58:e4-e6.
153. Czaja A.J., Carpenter H.A., Lindor K.D. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999, 30:1381-1386.
154. Czaja A.J., Lindor K.D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000, 119:1312-1316.
155. Burak K.W., Urbanski S.J., Swain M.G. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998, 29:990-993.
156. Venkataramani A., Jones M.B., Sorrell M.F. Methotrexate therapy for refractory chronic active autoimmune hepatitis. Am J Gastroenterol 2001, 96:3432-3434.
157. Vallone T.M., Ditelberg J., Kaplan M.M. Reversal of cirrhosis in a patient with primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Dig Dis Sci 2005, 50:167-170.
158. Moreno-Otero R., Garcia-Buey L., Garcia-Sanchez A., et al. Autoimmune hepatitis after long-term methotrexate therapy for rheumatoid arthritis. Curr Drug Saf 2011, 6:197-200.
159. Ksouda K., Affes H., Atheymen R., et al. Autoimmune hepatitis as an adverse effect of long-term methotrexate therapy. Indian J Pharmacol 2014, 46:649-650.
160. Khokhar O.S., Lewis J.H. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010, 28:508-518.
161. Sharzehi K., Huang M.A., Schreibman I.R., et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010, 24:588-592.
162. Hlivko J.T., Shiffman M.L., Stravitz R.T., et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008, 6:1036-1040.
163. Czaja A.J., Carpenter H.A. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005, 39:819-825.
164. Chatur N., Ramji A., Bain V.G., et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005, 25:723-727.
165. Inductivo-Yu I., Adams A., Gish R.G., et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007, 5:799-802.
166. Czaja A.J. Emerging treatments for autoimmune hepatitis. Curr Drug Targets Inflamm Allergy 2002, 1:317-326.
167. Vierling J.M., Flores P.A. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002, 6:825-850. ix.
168. Czaja A.J. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des 2011, 17:3120-3140.
169. Czaja A.J. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol 2012, 26:615-620.
170. Van Thiel D.H., Wright H., Carroll P., et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis-results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:771-776.
171. Aqel B.A., Machicao V., Rosser B., et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004, 38:805-809.
172. Tannous M.M., Cheng J., Muniyappa K., et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011, 34:405-407.
173. Larsen F.S., Vainer B., Eefsen M., et al. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007, 13:3232-3236.
174. Sherman K.E., Narkewicz M., Pinto P.C. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994, 21:1040-1047.
175. Fernandes N.F., Redeker A.G., Vierling J.M., et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999, 94:241-248.
176. Sciveres M., Caprai S., Palla G., et al. Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther 2004, 19:209-217.
177. Malekzadeh R., Nasseri-Moghaddam S., Kaviani M.J., et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001, 46:1321-1327.
178. Chatrath H., Allen L., Boyer T.D. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med 2014, 127:1128-1131.
179. Ytting H., Larsen F.S. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol 2015, 50:1025-1031.
180. Kerkar N., Dugan C., Rumbo C., et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005, 5:1085-1089.
181. Casanovas T., Argudo A., Pena-Cala M.C. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports. Transplant Proc 2011, 43:2233-2236.
182. Santos E.S., Arosemena L.R., Raez L.E., et al. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006, 26:625-629.
183. Barth E., Clawson J. A case of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol 2010, 4:502-509.
184. Carey E.J., Somaratne K., Rakela J. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Rev Med Chil 2011, 139:1484-1487.
185. Al-Busafi S.A., Michel R.P., Deschenes M. Rituximab for refractory autoimmune hepatitis: a case report. Arab J Gastroenterol 2013, 14:135-138.
186. Weiler-Normann C., Schramm C., Quaas A., et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013, 58:529-534.
187. Fujii K., Rokutanda R., Osugi Y., et al. Adult-onset Still's disease complicated by autoimmune hepatitis: successful treatment with infliximab. Intern Med 2012, 51:1125-1128.
188. Mancini S., Amorotti E., Vecchio S., et al. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010, 5:193-200.
189. Goldfeld D.A., Verna E.C., Lefkowitch J., et al. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case. Dig Dis Sci 2011, 56:3386-3388.
190. van Casteren-Messidoro C., Prins G., van T.A., et al. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis 2012, 6:630-631.
191. Dang L.J., Lubel J.S., Gunatheesan S., et al. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol 2014, 55:75-79.
192. Adar T., Mizrahi M., Pappo O., et al. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010, 44:e20-e22.
193. Efe C. Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship?. Autoimmun Rev 2013, 12:337-339.
194. Schramm C., Bubenheim M., Adam R., et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl 2010, 16:461-469.
195. Tanaka T., Sugawara Y., Kokudo N. Liver transplantation and autoimmune hepatitis. Intractable Rare Dis Res 2015, 4:33-38.
196. Czaja A.J. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci 2012, 57:2248-2266.
197. Dbouk N., Parekh S. Impact of pretransplant antinuclear antibody and antismooth muscle antibody titers on disease recurrence and graft survival following liver transplantation in autoimmune hepatitis patients. J Gastroenterol Hepatol 2013, 28:537-542.
198. Manns M.P., Bahr M.J. Recurrent autoimmune hepatitis after liver transplantation: when non-self becomes self. Hepatology 2000, 32:868-870.
199. Czaja A.J. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl 2002, 8:505-513.
200. Rosen H.R., Hinrichs D.J., Leistikow R.L., et al. Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. J Immunol 2004, 173:5355-5359.
201. Ratziu V., Samuel D., Sebagh M., et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999, 30:131-141.
202. Schreuder T.C., Hubscher S.G., Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far?. Transpl Int 2009, 22:144-152.
203. Duclos-Vallee J.C., Sebagh M., Rifai K., et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003, 52:893-897.
204. Ayata G., Gordon F.D., Lewis W.D., et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 2000, 32:185-192.
205. Gautam M., Cheruvattath R., Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006, 12:1813-1824.
206. Milkiewicz P., Hubscher S.G., Skiba G., et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999, 68:253-256.
207. Hurtova M., Duclos-Vallee J.C., Johanet C., et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl 2001, 7:556-558.
208. Gonzalez-Koch A., Czaja A.J., Carpenter H.A., et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001, 7:302-310.
209. Rowe I.A., Webb K., Gunson B.K., et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008, 21:459-465.
210. Ilyas J.A., O'Mahony C.A., Vierling J.M. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol 2011, 25:765-782.
211. Guido M., Burra P. De novo autoimmune hepatitis after liver transplantation. Semin Liver Dis 2011, 31:71-81.
212. Kerkar N., Hadzic N., Davies E.T., et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998, 351:409-413.
213. Heneghan M.A., Portmann B.C., Norris S.M., et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001, 34:464-470.
214. Oikonomou K.G., Zachou K., Dalekos G.N. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev 2011, 10:389-396.
215. Kanno Y., Watanabe H., Takahashi A., et al. Anti-phosphoenolpyruvate carboxykinase 2 antibody in patients with autoimmune hepatitis. Hepatol Res 2013.
216. Calich A.L., Viana V.S., Cancado E., et al. Anti-ribosomal P protein: a novel antibody in autoimmune hepatitis. Liver Int 2013, 33:909-913.
217. Yokokawa J., Kanno Y., Abe K., et al. Anti-nucleosome autoantibodies as markers for autoimmune hepatitis and their correlation with disease activity. Hepatol Res 2014, 44:420-428.
218. Matsumoto K., Miyake Y., Matsushita H., et al. Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. J Gastroenterol Hepatol 2014, 29:110-115.
219. Zingaretti C., Arigo M., Cardaci A., et al. Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. Mol Cell Proteomics 2012, 11:1885-1897.
220. Peedikayil M.C., Dahhan T.I., Al Ashgar H.I. Nitrofurantoin-induced fulminant hepatitis mimicking autoimmune hepatitis. Ann Pharmacother 2006, 40:1888-1889.
221. Alla V., Abraham J., Siddiqui J., et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006, 40:757-761.
222. Miao Q., Bian Z., Tang R., et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin Rev Allergy Immunol 2015, 48:226-235.
223. Gatselis N.K., Zachou K., Koukoulis G.K., et al. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol 2015, 21:60-83.